Lupus Nephritis: Novel Treatments and Diagnostic Approaches
Tóm tắt
Over the last decade, therapy for lupus nephritis in children has begun to shift from the provision of long-term steroids and intravenous cyclophosphamide to regimens with limited or no cyclophosphamide, lower steroid burdens, and increased reliance on oral mycophenolate mofetil. As the molecular immunology underlying the pathophysiology of lupus is further discerned, more targeted therapies, including the use of monoclonal antibodies against immune cells or cell signaling factors, may come to play a larger role in the treatment of pediatric lupus. Similarly, as experience with autologous stem cell transplantation for therapy-resistant disease is gained in adults, its potential applicability to such situations in children may be clarified. Over the next few decades, children with lupus will benefit as well from the identification of new biomarkers that are both sensitive and specific to disease activity, allowing clinicians to more readily assess response to therapy and diagnose disease flare.
Tài liệu tham khảo
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61–4.
•• Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11:357–64.
•• Rovin BH, Furie F, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64:1215–26.
Klein-Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am. 2002;28:561–77.
Costallat LT, Coimbra AM. Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol. 1994;12:603–7.
Brunner HI, Gladman DD, Ibañez D, et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58:556–62.
Austin HA 3rd, Klippel JH, Balow JE. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614–9.
Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121–31.
•• Appel GB, Contreras G, Dooley MA, et al. Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.
Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;24:2219–28.
Houssiau FA, D’Cruz D, Sangle S, et al. MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083–9.
Dooley MA, Jayne D, Ginzler EM, et al. ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886–95.
Koo HS, Kim YC, Lee SW, et al. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Lupus. 2011;20:1442–9.
Arends S, Grootscholten C, Derksen RH, et al. Dutch Working Party on systemic lupus erythematosus. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis. 2012;71:966–73.
• Sundel R, Solomons N, Lisk L. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus. 2012;21:1433–43.
Pereira T, Abitbol CL, Seeherunvong W, Katsoufis C, Chandar J, Freundlich M, Zilleruelo G. Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol. 2011;6:2192–9.
Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology. 2010;49:128–40.
Mohan S, Radhakrishnan J. Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol. 2011;75:233–41.
Zavada J, Pesickova S, Rysava R, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010;19:1281–9.
Griffiths B, Emery P, Ryan V, et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology. 2010;49:723–32.
Austin HA 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009;20:901–11.
Aragon E, Chan YH, Ng KH, et al. Good outcomes with mycophenolate–cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus. 2010;19:965–73.
Baca V, Catalán T, Villasís-Keever M, et al. Effect of low-dose cyclosporine A in the treatment of refractory proteinuria in childhood-onset lupus nephritis. Lupus. 2006;15:490–5.
Sakuma S, Kato Y, Nishigaki F, et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130:1655–63.
Deng J, Huo D, Wu Q, Yang Z, Liao Y. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med. 2012;227:281–8.
Lee YH, Lee HS, Choi SJ, Dai Ji J, Song GG. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20:636–40.
Wang S, Li X, Qu L, et al. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus. 2012;21:1025–35.
Chen W, Liu Q, Chen W, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus. 2012;21:944–52.
Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012;27:1467–72.
Fernandez D, Bonilla E, Mirza N, et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;2006:54.
Clinical Trials Registry. www.clinicaltrials.gov. Accessed Oct 2012.
Wang HY, Cui TG, Hou FF, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus. 2008;17:638–44.
Xiong W, Lahita RG. Novel treatments for systemic lupus erythematosus. Ther Adv Musculoskelet Dis. 2011;3:255–66.
Steinmetz OM, Velden J, Kneissler U, et al. Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis. Kidney Int. 2008;74:448–57.
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–45.
Fernandez-Nebro A, de la Fuente JM, Carreno L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2012;21(1063):1–76.
•• Merrill JT, Buyon JP, Furie RA, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011;20:709–16.
FDA Alert for Rituximab (marketed as Rituxan). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109106.htm. Accessed Nov 2012.
Schmedt N, Andersohn F, Garbe E. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2012;21:1216–20.
Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:2652–61.
Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–8.
Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31.
Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74.
UCB News Press Release: new data from EMBLEM study shows pipeline drug Epratuzumab provided significant efficacy for patients suffering from moderate to severe systemic lupus erythematosus. http://hugin.info/133973/R/1424204/372863.pdf.
Horowitz DM, Furie RA. Abetimus sodium: a medication for the prevention of lupus nephritis flares. Expert Opin Pharmacother. 2009;10:1501–7.
Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled Phase III trial. Arthritis Rheum. 2008;58:2470–80.
Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719–27.
Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open phase 1 dosage-escalation study. Arthritis Rheum. 2010;62:542–52.
Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics, and safety of a human anti-IL6 monoclonal antibody (sirukumab) in healthy subjects in a first in-human study. Br J Clin Pharmacol. 2011;72:270–81.
Ahluwalia JP. Immunotherapy in inflammatory bowel disease. Med Clin North Am. 2012;96:525–44.
Aringer M, Houssaiu F, Gordon C, et al. Adverse events and efficacy of TNF-a blockade with infliximab in patients with systemic lupus erythematosus: long-term follow up of 13 patients. Rheumatology. 2009;48:1451–4.
Deepak P, Sifuentes H, Sherid M, et al. T-cell non-hodgkin’s lymphomas reported to the FDS AERS with tumor necrosis factor-alpha (TNF-a) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2012. doi:10.1038/ajg.2012.334.
Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus. Arthritis Rheum. 2010;62:3077–87.
Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from the BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12:630–9.
Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase 1, multicenter, double blind randomized study. Ann Rheum Dis. 2011;70:1905–13.
Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-a/b-inducible genes and downstream effect in a phase I trial of an anti-interferon-a monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785–96.
McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics results of rontalizumab in a phase 1, placebo controlled, double blind, dose-escalation study in systemic lupus erythematosus. Arthritis Rheum. 2012;64(11):3666–76.
Kaliyaperumal A, Michaels MA, Datta SK. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol. 1999;162:5775–83.
Muller S, Monneauz F, Schall N, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus. Arthritis Rheum. 2008;58:3873–83.
Immupharma: Lupuzor-treatment for Lupus. http://www.immupharma.org/lupuzor. Accessed Nov 2012.
• Mascarenhas S, Avalos B, Ardoin SP. An update on stem cell transplantation in autoimmune rheumatologic disorders. Curr Allergy Asthma Rep. 2012;12(6):530–40.
Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13:168–76.
Marmont A. Allogeneic hematopoietic stem cell transplantation for severe autoimmune diseases: great expectations but controversial evidence. Bone Marrow Transplant. 2006;38:1–4.
Stagg J, Galipeau J. Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol. 2007;150:45–66.
Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62:2467–75.
Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389–97.
Talaulikaur D, Tymms KE, Prosser I, et al. Autologous peripheral blood stem cell transplantation with in vivo T-cell depletion for life threatening refractory systemic lupus erythematosus. Lupus. 2005;14:159–63.
Moore J, Brooks P, Milliken S, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hematopoietic stem cell transplantation for severe refractory rheumatoid arthritis. Arthritis Rheum. 2002;46:2301–9.
Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006;295:527–35.
Euler HH, Marmont AM, Bacigalupo A, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood. 1996;88:3621–5.
Illei GG, Cervera R, Burt RK, et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis. 2011;70:2071–4.
Burt RK, Marmont A, Oyama Y, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum. 2006;54:3750–60.
•• Wakasugi D, Gono T, Kawaguchi Y, et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol. 2012;39:79–85.
Marks SD, Williams SJ, Tullus K, et al. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. Nephrol Dial Transplant. 2008;23:3521–6.
Rovin BH, Song H, Birmingham DJ, et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol. 2005;16:467–73.
Singh S, Wu T, Xie C, et al. Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. Arthritis Res Ther. 2012;14:R164.
• Watson L, Midgley A, Pilkington C, et al. Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus. 2012;21:496–501.
Marks SD, Shah V, Pilkington C, et al. Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. Pediatr Nephrol. 2010;25:2283–8.
Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta. 2000;1482:272–83.
Goetz DH, Holmes MA, Borregaard N, et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002;10:1033–43.
Parikh CR, Devarajan P, Zappitelli M, et al. TRIBE-AKI Consortium. Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J Am Soc Nephrol. 2011;22:1737–47.
Brunner HI, Mueller M, Rutherford C, et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54:2577–84.
Suzuki M, Wiers KM, Klein-Gitelman MS, et al. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol. 2008;23:403–12.
Hinze CH, Suzuki M, Klein-Gitelman M, et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 2009;60:2772–81.
Daniel L, Sichez H, Giorgi R, et al. Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int. 2001;60:2215–21.
Abd-Elkareem MI, Al Tamimy HM, Khamis OA, et al. Increased urinary levels of the leukocyte adhesion molecules ICAM-1 and VCAM-1 in human lupus nephritis with advanced renal histological changes: preliminary findings. Clin Exp Nephrol. 2010;4:548–57.
Suzuki M, Ross GF, Wiers K, et al. Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr Nephrol. 2007;22:2047–57.
Suzuki M, Wiers K, Brooks EB, et al. Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Res. 2009;65:530–6.
• Brunner HI, Bennett MR, Mina R, et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 2012;64:2687–97.
Zhang X, Nagaraja HN, Nadasdy T, et al. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int. 2012;81:401–6.